< Grace L. Guo MBBS, Ph.D. » EOHSI Directory - EOHSI | EOHSI

Grace L. Guo , MBBS, Ph.D.

Professor Rutgers University – Ernest Mario School of PharmacyEOHSI – Toxicology
Photo of Grace L. Guo MBBS, Ph.D.

Biography

Dr. Guo is an Associate Professor at the Department Pharmacology and Toxicology in the Ernest Mario School of Pharmacy of Rutgers University. She is an adjunct faculty of the Department of Pharmacology, Toxicology and Therapeutics in School of Medicine at the University of Kanas Medical Center.  Dr. Guo obtained her MBBS degree from the West China University of Medical Sciences in 1993 and a PhD degree from the University of Kansas Medical Center in 2001, as well as post-doctoral training at the NCI, NIH in 2004. From 2004-2012, Dr. Guo has served as a faculty at the University of Kansas Medical Center.

Research Areas

Liver is essential for life and liver functions are tightly regulated. Particularly, the impact of intestine on liver homeostasis, function and diseases is significant, but this impact has been less studied. Our group has been focusing on determining the effects of intestine-liver crosstalks on liver metabolism and pathogenesis and the underlying molecular mechanisms, especially following disruption of endogenous homeostasis and exposure to xenobiotic chemicals.

Scholarly Activities

  • 2012: Presidential Poster Award, AASLD meeting (2)
  • 2011: Presidential Poster Award, AASLD meeting
  • 2010: Presidential Poster Award, AASLD meeting
  • 2009: Presidential Poster Award, AASLD meeting
  • 2009: Post award winner for Annual Liver Center Symposium, University of Kansas Medical Center
  • 2007: First place in oral presentation in Annual Cancer Center Symposium, University of Kansas Medical Center
  • 2005: BIRCWH/NIH scholar

Recent Publications

  1. Taylor, R, Yang, Z, Henry, Z, Capece, G, Meadows, V, Otersen, K, Basaly, V, Bhattacharya, A, Mera, S, Zhou, P et al.. Characterization of individual bile acids in vivo utilizing a novel low bile acid mouse model. Toxicol Sci. 2024; :. doi: 10.1093/toxsci/kfae029. PubMed PMID:38526215
  2. Yang, X, Wang, J, Chang, CY, Zhou, F, Liu, J, Xu, H, Ibrahim, M, Gomez, M, Guo, GL, Liu, H et al.. Leukemia inhibitory factor suppresses hepatic de novo lipogenesis and induces cachexia in mice. Nat Commun. 2024;15 (1):627. doi: 10.1038/s41467-024-44924-w. PubMed PMID:38245529 PubMed Central PMC10799847
  3. Yang, Z, Zarbl, H, Guo, GL. Circadian Regulation of Endocrine Fibroblast Growth Factors on Systemic Energy Metabolism. Mol Pharmacol. 2024;105 (3):179-193. doi: 10.1124/molpharm.123.000831. PubMed PMID:38238100 PubMed Central PMC10877735
  4. Bhattacharya, A, Taylor, RE, Guo, GL. In vivo mouse models to study bile acid synthesis and signaling. Hepatobiliary Pancreat Dis Int. 2023;22 (5):466-473. doi: 10.1016/j.hbpd.2023.08.009. PubMed PMID:37620226 PubMed Central PMC10790561
  5. Meadows, V, Yang, Z, Basaly, V, Guo, GL. FXR Friend-ChIPs in the Enterohepatic System. Semin Liver Dis. 2023;43 (3):267-278. doi: 10.1055/a-2128-5538. PubMed PMID:37442156 PubMed Central PMC10620036
  6. Meshanni, JA, Lee, JM, Vayas, KN, Sun, R, Jiang, C, Guo, GL, Gow, AJ, Laskin, JD, Laskin, DL. Suppression of Lung Oxidative Stress, Inflammation, and Fibrosis following Nitrogen Mustard Exposure by the Selective Farnesoid X Receptor Agonist Obeticholic Acid. J Pharmacol Exp Ther. 2024;388 (2):586-595. doi: 10.1124/jpet.123.001557. PubMed PMID:37188530 PubMed Central PMC10801770
  7. Henry, Z, Meadows, V, Guo, GL. FXR and NASH: an avenue for tissue-specific regulation. Hepatol Commun. 2023;7 (5):. doi: 10.1097/HC9.0000000000000127. PubMed PMID:37058105 PubMed Central PMC10109454
  8. Taylor, R, Armstrong, L, Bhattacharya, A, Henry, Z, Brinker, A, Buckley, B, Kong, B, Guo, G. Myclobutanil-mediated alteration of liver-gut FXR signaling in mice. Toxicol Sci. 2023;191 (2):387-399. doi: 10.1093/toxsci/kfac129. PubMed PMID:36511616 PubMed Central PMC9936201
  9. Murray, A, Banota, T, Guo, GL, Smith, LC, Meshanni, JA, Lee, J, Kong, B, Abramova, EV, Goedken, M, Gow, AJ et al.. Farnesoid X receptor regulates lung macrophage activation and injury following nitrogen mustard exposure. Toxicol Appl Pharmacol. 2022;454 :116208. doi: 10.1016/j.taap.2022.116208. PubMed PMID:35998709 PubMed Central PMC9960619
  10. Jiang, M, Li, F, Liu, Y, Gu, Z, Zhang, L, Lee, J, He, L, Vatsalya, V, Zhang, HG, Deng, Z et al.. Probiotic-derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation. Hepatology. 2023;77 (4):1164-1180. doi: 10.1002/hep.32608. PubMed PMID:35689610 PubMed Central PMC9741667
Search PubMed
Connections Business Directory | Leaflet | © OpenStreetMap contributors

EOHSI Room 322 Piscataway NJ 08854